Founder and CEO of the Company (HKEX: 1477). Responsible for overall strategic planning, business guidance, and daily management of the company. Mr. Liu Ye has over 32 years of experience in the pharmaceutical industry. He served as the Chairman and General Manager of Santen Pharmaceutical (China) Co., Ltd. from October 2014 to July 2018. From February 2009 to September 2014, he served as the head of the pharmaceutical department at Eisai  (China) Pharmaceutical Co., Ltd., and later as the general manager, responsible for pharmaceutical affairs management and development as well as the overall operation of the company. In addition, Mr. Liu Ye has served as a director of EyePoint since January 2021.

Mr. Liu Ye obtained a Master's degree in Pharmacology from Dalhousie University in Canada in August 2003. Graduated from Shanghai Medical University in July 1993 with a Bachelor of Science degree in Pharmaceutical Chemistry.

 joined our Group in September 3, 2018 as the vice president of registration affairs. He has been our executive director since April 24, 2020, and our chief development officer since June 1, 2020. Dr. Hu is primarily responsible for participating in strategic planning and management of CMC and registration affairs. Dr. Hu has around 20 years of experience in pharmaceutical industry. From July 2006 to August 2018, he held positions including plant technique and registration group manager, registration and pharmaceutical department director, clinical development department director and internal audit department director in Santen Pharmaceutical (China) Co., Ltd., mainly responsible for clinical development compliance and other drug-related regulations and compliance.

Dr. Hu obtained his PhD in Pharmacokinetics from Kyoto Pharmaceutical University, Japan in March 2002, and his Master's degree in Pharmaceutics in March 1999. He also earned his Bachelor's degree in Pharmacy from Shenyang Pharmaceutical University, China in July 1996.

She is responsible for leading clinical development. She joined the Group on 1 April 2019 as the Director of Clinical Medicine. She has been the Vice President of Registration Affairs since 1 October 2022. Prior to joining the Group, Dr. Shen served as the manager of the medical information department of Santen Pharmaceutical (China) Co., Ltd. from September 2015 to March 2019. From August 2013 to September 2015, She served as the medical information manager in Shanghai Roche Pharmaceutical Co., Ltd. From July 2010 to July 2012,she served as a postdoctoral fellow at the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences.

Dr. Shen obtained his doctorate degree in pharmacology from China Pharmaceutical University in June 2010. She graduated from College of Medicine of Zhengzhou University in June 2005 with a bachelor's degree in pharmacy.

has been our chief commercial officer since January 1, 2021, responsible for product commercialization. Mr. Zuo served as our vice president of commercialization from September 2018 to January 2021. Prior to joining our Group, Mr. Zuo held positions including manager of business development department, director of business development department and head of sales of the pharmaceutical department of Santen Pharmaceutical (China) Co., Ltd. from April 2015 to August 2018. From October 2010 to March 2015, he successively served as associate product manager and district sales manager of gastrointestinal and liver diseases department in Eisai (China) Inc., where he was responsible for sales of drugs. From June 2009 to September 2010, he served as a preclinical project manager of R&D department in Shanghai Hengrui Pharmaceutical Co., Ltd. (上海恒瑞医药有限公司).

Mr. Zuo obtained his master’s degree in pharmacology in Shanghai Institute of Pharmaceutical Industry (上海医药工业研究院) in May 2009. He graduated with bachelor’s degree in pharmacy from Yantai University (烟台大学) in June 2006.